(Adds details, shares)
Dec 12 Alexion Pharmaceuticals Inc,
which is investigating allegations regarding some of its sales
practices over its flagship drug, said its chief executive
officer and chief financial officer resigned, effective
Alexion's shares were down 13.3 percent at $114.80 in
premarket trading on Monday.
The company said David Hallal had resigned as CEO and that
it had named David Brennan, board member and former AstraZeneca
Plc chief, as his interim replacement.
Alexion had disclosed last month that it was investigating
allegations made by a former employee regarding sales practices
involving its costly blood disorder drug, Soliris.
The investigation, which is nearing completion, had not
identified any facts that require the company to update its
previously reported historical results at this point in time,
Alexion said on Monday.
Soliris, approved for rare blood disorders paroxysmal
nocturnal hemoglobinuria and atypical hemolytic uremic syndrome,
had sales of $2.59 billion in 2015.
The company also said Chief Financial Officer Vikas Sinha
left to pursue other opportunities and would be succeeded by
David Anderson, who was earlier CFO at Honeywell International
Hallal, who joined Alexion in 2006, had been appointed the
company's CEO in April 2015.
Spencer Stuart has been engaged to search for a permanent
CEO, Alexion said.
Alexion, which had delayed filing its quarterly report for
the period ended Sept. 30 due to the investigation, said it
expected to file its report by January.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj
Kalluvila and Anil D'Silva)